Anavex Life Sciences (AVXL) Shareholder's Equity Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.14% |
| Sep 30, 2025 | -12.68% |
| Jun 30, 2025 | -15.50% |
| Mar 31, 2025 | -13.14% |
| Dec 31, 2024 | -8.83% |
| Sep 30, 2024 | -7.27% |
| Jun 30, 2024 | -6.18% |
| Mar 31, 2024 | 21.20% |
| Dec 31, 2023 | 43.06% |
| Sep 30, 2023 | 73.34% |
| Jun 30, 2023 | 81.17% |
| Mar 31, 2023 | 80.24% |
| Dec 31, 2022 | 73.30% |
| Sep 30, 2022 | 91.50% |
| Jun 30, 2022 | 92.33% |
| Mar 31, 2022 | 106.90% |
| Dec 31, 2021 | 95.92% |
| Sep 30, 2021 | 89.05% |
| Jun 30, 2021 | 88.17% |
| Mar 31, 2021 | 49.96% |
| Dec 31, 2020 | 21.92% |
| Sep 30, 2020 | 1.71% |
| Jun 30, 2020 | 1.72% |
| Sep 30, 2019 | 47.61% |
| Sep 30, 2018 | 20.34% |
| Jun 30, 2018 | 53.12% |
| Mar 31, 2018 | 68.46% |
| Dec 31, 2017 | 277.96% |
| Sep 30, 2017 | 412.20% |
| Jun 30, 2017 | 46.83% |
| Sep 30, 2016 | 65.84% |
| Sep 30, 2015 | 86.19% |
| Jun 30, 2015 | 70.87% |
| Mar 31, 2015 | 53.34% |
| Sep 30, 2014 | 29.44% |
| Sep 30, 2013 | 5.94% |